Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,951Revenue $M0Net Margin (%)0Z-Score
Enterprise Value $M4,946EPS $0Operating Margin %0F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio0Cash flow > EarningsN
Price/Sales05-y EBITDA Growth Rate %0Current Ratio0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %ROA % (ttm)0Higher Current Ratio y-yN
Dividend Yield %2.0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M0ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with XLV

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
XLVKen Fisher 2014-06-30 Add0.01%$55.71 - $61.23
($58.7)
$ 73.0420%Add 34.36%226,412
XLVJohn Burbank 2014-03-31 Buy 0.03%$54.86 - $60.12
($57.55)
$ 73.0421%New holding17,173
XLVGeorge Soros 2012-09-30 Sold Out -0.03%$37.27 - $40.3
($38.73)
$ 73.0447%Sold Out0
XLVGeorge Soros 2012-06-30 Buy 0.03%$35.52 - $37.87
($36.91)
$ 73.0449%New holding50,000
XLVKen Fisher 2011-06-30 Buy 0.01%$33.28 - $36.42
($34.99)
$ 73.0452%New holding86,997
XLVGeorge Soros 2010-12-31 Reduce-0.15%$30.19 - $31.78
($31.13)
$ 73.0457%Reduce -93.88%34,153
XLVGeorge Soros 2010-09-30 Buy 0.25%$28.03 - $30.68
($29.2)
$ 73.0460%New holding558,053
XLVGeorge Soros 2009-12-31 Buy 0.01%$28.07 - $31.62
($30.04)
$ 73.0459%New holding11,700
XLVBill Gates 2009-06-30 Sold Out -4.19%$23.76 - $26.53
($25.04)
$ 73.0466%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XLV is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


XLV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Gagnon, RobertDirector, Senior Officer 2015-03-27Buy10,000$0.07104242.86view
Savage, Alan Clyde Hayes10% Security Holder 2015-03-27Sell20,000$0.898106.74view
Christopoulos, George10% Security Holder 2015-03-27Buy3,000$10.3609.13view
Babatz, GuillermoDirector 2015-03-27Buy819$62.1217.58view
Janssen, Gerardus AdrianusDirector 2015-03-27Buy400$30143.47view
Farrar, JefferySenior Officer 2015-03-27Buy8,100$0.759638.67view
beukman, eugeneDirector 2015-03-27Sell100,000$0.02365100view
Travis, Adam RobertDirector, Senior Officer 2015-03-27Buy8,000$0.1260766.67view
laberge, sylvainSenior Officer 2015-03-27Buy10,000$0.05145980view
Doucet, RogerDirector 2015-03-27Buy25,000$0.1356084.62view

Press Releases about XLV :

    Quarterly/Annual Reports about XLV:

      News about XLV:

      Articles On GuruFocus.com
      S&P 500 Sector ETFs: A Look Under the Hood, Part 3 Mar 11 2015 
      Build a “Whatever Happens” Portfolio – Now! Aug 15 2014 
      Are Earnings Important? These Days, Revenues Count for More! Mar 17 2014 

      More From Other Websites
      What Drives Generic Pharmaceuticals’ Valuation? Mar 28 2015
      Generic Companies Are Fighting for Market Share Mar 28 2015
      Specialty Generics: Why Are They Getting More Attention? Mar 28 2015
      Affordable Pricing Is Driving the Generic Drug Market Mar 28 2015
      How Aetna Generates Value for its Shareholders Mar 28 2015
      Farallon Capital Increases Position in Covidien Mar 28 2015
      The Pharmacyclics–AbbVie Merger: What Are the Details? Mar 28 2015
      How Does Aetna Compare with Its Peers in Valuation? Mar 28 2015
      How the NAIC’s Capital Requirements Affect Aetna Mar 28 2015
      How Does Aetna Compare to Its Peers in Medical Care Ratio? Mar 28 2015
      How Aetna Plans to Improve Quality of Care and Reduce Costs Mar 28 2015
      Pfizer: A Leading Pharmaceutical Company Mar 27 2015
      Not another Bubble: Why the NASDAQ is a Different Index Now Mar 27 2015
      Pisani sorts through volatile trading Mar 26 2015
      UnitedHealth Group’s payment strategy evolved in 2014 Mar 25 2015
      Good time for investors to jump in: Pro Mar 25 2015
      Why Is the Generics Industry Controlled by Regulations? Mar 25 2015
      Bargaining Power Is in the Hands of the Distribution Industry Mar 25 2015
      Here's how to protect your profits in biotech: Trader Mar 24 2015
      Health check: Obamacare 5 years later Mar 24 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK